Provided by Tiger Trade Technology Pte. Ltd.

GlaxoSmithKline PLC

50.87
+0.43000.85%
Pre-market: 50.00-0.8700-1.71%08:24 EDT
Volume:2.44M
Turnover:124.01M
Market Cap:102.89B
PE:16.27
High:51.52
Open:51.50
Low:50.19
Close:50.44
52wk High:61.70
52wk Low:39.18
Shares:2.02B
Float Shares:1.94B
Volume Ratio:0.84
T/O Rate:0.13%
Dividend:1.84
Dividend Rate:3.62%
EPS(TTM):3.13
EPS(LYR):3.74
ROE:33.38%
ROA:10.01%
PB:4.31
PE(LYR):13.62

Loading ...

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
18 hours ago

Deutsche Bank Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

TIPRANKS
·
Sep 02

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

Barclays Keeps Their Sell Rating on GlaxoSmithKline (GSK)

TIPRANKS
·
Sep 01

GSK Advances Early-Stage Lung Drug With New Formulation Study

TIPRANKS
·
Aug 28

GSK Slips Thursday, Underperforms Market

Dow Jones
·
Aug 28

GSK’s Pediatric Asthma Trial Signals Long-Term Upside in Biologic Market

TIPRANKS
·
Aug 27

GSK Names Tina Graves President, General Manager for Canada

Reuters
·
Aug 26

GSK price target raised to 1,900 GBp from 1,750 GBp at Morgan Stanley

TIPRANKS
·
Aug 26

Morgan Stanley Keeps Their Sell Rating on GlaxoSmithKline (GSK)

TIPRANKS
·
Aug 25

GlaxoSmithKline (GSK) Gets a Hold from Deutsche Bank

TIPRANKS
·
Aug 25

Barclays Sticks to Their Sell Rating for GlaxoSmithKline (GSK)

TIPRANKS
·
Aug 25

GSK Slips Monday, Underperforms Market

Dow Jones
·
Aug 25

GSK US President Sells Over 44,000 American Depositary Shares

TIPRANKS
·
Aug 24

Exchange-Traded Funds, Equity Futures Fall Pre-Bell Monday as Investors Await Details on US Sanctions Against Iran

MT Newswires Live
·
Aug 24

GSK Says Chronic Hepatitis B Treatment Approved in Japan

MT Newswires Live
·
Aug 24

GSK Says Jemperli Accepted for Priority Review as Potential Treatment for Rectal Cancer

MT Newswires Live
·
Aug 24

GSK wins first global approval for hepatitis B functional cure in Japan

TIPRANKS
·
Aug 24

GSK’s New COPD Bet: Felcorekibart Enters Phase 3 With Long-Term Upside Potential

TIPRANKS
·
Aug 22

GSK’s New Phase 3 Asthma Trial Sets the Stage for the Next Wave in Respiratory Growth

TIPRANKS
·
Aug 22